Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

In September, the use of a Sanofi immuno-inflammatory medicine to treat chronic obstructive pulmonary disease (COPD) was ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Sanofi and Regeneron, meanwhile, have other irons in the COPD fire, notably itepekimab, an antibody that inhibits IL-33 that could be used in a broader spectrum of patients. It is in two phase 3 ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

French drugmaker Sanofi has said. Reuters Health Information, May 22, 2023 ATS 2023 Dupilumab Curbs Acute COPD Exacerbations Patients treated with dupilumab for COPD also showed significant ...